Searching WA 0812 2782 5310 Pusat Pembuatan Rumah Type 36/72 1 Lantai Imogiri Bantul on page 1

Workspan Daily article;As Interest in GLP-1 Drugs Spikes, Employers Weigh the Costs, Benefits , Workspan Daily article;Employers Grapple with the Rising Costs and Popularity of Specialty Weight-Loss Drugs , Workspan Daily article;Benefits and Well-Being Tech Demo Day , on-demand webinar; As demand for glucagon-like peptide-1 (GLP-1) medications soars, so do health insurance costs.

The report suggests the increasing use of glucagon-like peptide-1 (GLP-1) drugs to manage metabolic conditions has intensified pressure on healthcare costs.; ;72: The percentage of American workers who said they’re not where they expected to be professionally, according to a new survey from career website MyPerfectResume.

For WorldatWork Members Considerations to Manage the Costs of GLP-1 Coverage , Workspan Daily Plus+ article;Total Rewards Inventory of Programs & Practices , research;Total Rewards Inventory Checklist , tool;Five Emerging Workplace Trends Affecting the Employee Experience , Journal of Total Rewards article; For Everyone As Interest in GLP-1 Drugs Spikes, Employers Weigh the Costs, Benefits , Workspan Daily article;Employers Grapple with the Rising Costs and Popularity of Specialty Weight-Loss Drugs , Workspan Daily article;Most Employers Hold Firm on Well-Being Offerings — But Want Results , Workspan Daily article;As Health Costs Spike, Total Rewards and CFO Collaboration Is Crucial , Workspan Daily article;Employers Facing Healthcare Cost Containment Challenge for 2025 , Workspan Daily article; Glucagon-like peptide-1 (GLP-1) medications are more top-of-mind than ever this year for employees — and they’re looking to their employers to help pay for

This survey by Harris Pool for Express Employment Professionals showed that 72% of workers between 54 and 72 years old would prefer a semi-retirement flexible work schedule.

For WorldatWork Members Total Rewards Inventory of Programs & Practices , research;5 Health Benefits Trends Come into Focus for 2024 , Workspan Magazine article;Navigating Employees’ Serious Medical Needs , on-demand webinar;Total Rewards Inventory Checklist , tool; As the demand for glucagon-like peptide-1 (orGLP-1) drugs increases, and the potential applications of them continue to expand (from diabetes management to obesity and beyond), employers are weighing both the cost of covering the medications and the potential long-term benefit (to employees and the organization).

The Potential ROI for Covering GLP-1s , Workspan Daily Plus+ article;Beyond the Rx: Maximizing GLP-1 Value Through Employee Support , Workspan Daily Plus+ article;Health Insurance Selection Checklist for Employees , Workspan Daily Plus+ article;Health Plan Compliance Calendar , tool;Total Rewards Inventory of Programs & Practices , research; Eighty percent of employers report glucagon-like peptide-1 (GLP-1) medications are driving increases in healthcare costs , but the demand for these drugs isn’t going away — leaving HR functions and their rewards professionals to walk the tightrope between improving employee health outcomes and balancing bottom-line costs.

; ;The Impact of the H.R. 1 Law on the Telehealth Safe Harbor; ;How H.R. 1 Changes Your Section 127 and 529 Education Programs;Charting the Changes: 2026 Benefit Plan Limitations; Additional Workspan Daily Plus+ articles related to H.R 1: ;Checklist for Total Rewards to Be Compliant with H.R. 1 Provisions; ;The Ripple Effect: 529 Plans as a Catalyst for Financial Stability;What Are TR Pros’ Options for Paid Care Leave Design; Compensation and Payroll System Updates In the area of payroll and compensation, experts shared these system updates may be required: ;W-2s need to include reporting fields that separate qualified overtime compensation from base pay.

According to a Robert Half report, only 36% of workers planned to look for a job in early 2024, compared to 49% last summer.

It also fills in the gaps from other recent government guidance and mandates, including the H.R. 1 law (also known as the One Big Beautiful Bill Act) and releases from the IRS ( in May ) and the Department of Health and Human Services ( in June ).

Cody Midlam, a pharmacy community director at consulting firm WTW, noted there are already many potential “partners” in this space, such as: ;Clinical vendors to support weight loss with or without GLP-1 drugs;; ;Vendors to facilitate various payment structures for GLP-1 drugs;; ;PBM programs;; ;Health plan programs; and,; ;Combinations of all the above.; “Because the list price cut does not guarantee lower net costs for employers, it is unlikely to materially expand coverage of GLP-1 drugs for obesity,” he said.